Saturday, April 9, 2011

Lupus Initiative Story Bank—Tell Your Lupus Story!

Because the most memorable lessons come from real life

Wednesday, March 9, 2011

FDA APPROVES BENLYSTA® FOR LUPUS IN BREAKTHROUGH FOR MILLIONS OF SUFFERERS

Lupus Research Institute Welcomes First New Treatment Approved For Lupus in More Than 50 Years

Tuesday, March 8, 2011

LRI Awards Wide-Ranging Research Grants to Drive Next Generation of Scientific Discovery in Lupus

Commits $3.6 million for innovative studies to find new solutions for devastating disease with limited treatment options

Saturday, February 12, 2011

Identified: Regulatory Defect that Drives Lupus

LRI-Funded Scientist Dr. Harvey Cantor Leads Discovery

Friday, January 7, 2011

Mitigate Risk and Increase Success of Lupus Clinical Trials

Key LRI Conference Design Strategies Reach 11,500 Rheumatologists Residents, Nurse Practitioners, and more…

Saturday, December 18, 2010

Surprising Culprit in Lupus Found, Published in Immunity

Lupus Research Institute Scientist Contributes to Discovery (Image: L. Teichmann)

Monday, December 6, 2010

Human Genome Sciences: FDA Postpones Ruling on Benlysta

LRI President Margaret G. Dowd comments: “Although the U.S. Food and Drug Administration (FDA) has postponed until March its decision on whether to approve Benlysta, the LRI remains encouraged by last month’s FDA Arthritis Advisory Committee’s vote to recommend the drug’s approval for the treatment of active lupus.”

Thursday, October 28, 2010

New Clinical Test to Predict Lupus Flares Moves Closer to the Market

Lupus Research Institute Investigator’s Innovative Discovery of a Simple Blood Test for Lupus Flares Now Licensed for Development

Monday, October 18, 2010

Lupus Research Institute: A Decade of Impact in Lupus Research

Post a Comment

Monday, October 18, 2010

Lupus Research Institute Leads Scientific Discovery, Innovation, Future Hope for Patients with Devastating Disease

Pioneering Organization Demonstrates 80% Success Rate by LRI-Funded Researchers, Generates $100 Million in Follow-On Funding in First 10 Years